Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
oncology
Animal models and cell-based assays accelerate preclinical development by providing a reliable translational platform, generating mechanistic understanding and supporting evaluation of safety and efficacy.
Preclinical oncology studies play a vital role in the drug development process, offering crucial insights into the efficacy, safety, and mechanisms of new cancer treatments. Data from oncology preclinical studies are crucial for regulatory approval and advancing cancer treatments to clinical trials. By investing in early studies, pharmaceutical companies can make informed decisions about which compounds to pursue, optimizing their drug pipeline. These studies may also support the development of targeted, personalized therapies, improving patient outcomes by tailoring treatments to genetic profiles and tumor characteristics.
We also offer a selection of syngeneic and xenograft animal models. These models are of great value for assessing efficacy and safety of potential new treatments and, at the same time, can help identify effective dosing strategies. Additionally, mechanisms of action, resistance pathways and potential biomarkers for patient selection can be explored using such models. In addition to classical cancer treatments we have a large focus on immuno-oncology, a rapidly advancing field in cancer therapy that focuses on harnessing the body’s immune system to fight cancer. Immuno-oncology therapies, including immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, and monoclonal antibodies, have revolutionized cancer treatment.
Apart from our in vivo facilities we also have a growing library of cancer cell lines that can be utlized in a variety of cell-based assays, such as cytotoxicity assays or antibody dependent cellular cytotoxicity assays. In combination with, for example, live imaging platforms or flow cytometry these types of assays can provide valuable data in a screening or proof of concept stage of drug development. Designing the right study is crucial for generating meaningful and reliable data. Truly labs can help you tailor your preclinical (immune-) oncology studies to your specific needs.
